Knee Osteoarthritis Pipeline Drugs Insights Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight

DelveInsight's "Knee Osteoarthritis Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in the Knee Osteoarthritis pipeline landscape. It covers the Knee Osteoarthritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Knee Osteoarthritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Knee Osteoarthritis Pipeline? Click here to explore the therapies and trials making headlines @ Knee Osteoarthritis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Knee Osteoarthritis Pipeline Report

* On 30 September 2025, ArthroBiologix Inc. conducted a study is to determine whether outcomes for patients receiving intra-articular platelet-rich plasma (PRP) injections for knee osteoarthritis are influenced by observation of the preparatory steps to the procedure. The viewing of the steps involved in the administration of PRP may increase the effectiveness of the treatment in comparison to patients who have not observed the preparatory steps.
* On 03 September 2025, Synartro AB organized a Phase 1/2a Study to Assess Safety, Tolerability, Systemic Exposure, and Preliminary Efficacy of Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis.
* DelveInsight's Knee Osteoarthritis Pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Knee Osteoarthritis treatment.
* The leading Knee Osteoarthritis Companies such as Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia and others.
* Promising Knee Osteoarthritis Therapies such as Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599 and others.

Want to know which companies are leading innovation in Knee Osteoarthritis? Dive into the full pipeline insights @ Knee Osteoarthritis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Knee Osteoarthritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Knee Osteoarthritis Pipeline Report also highlights the unmet needs with respect to the Knee Osteoarthritis.

Knee Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work.

Knee Osteoarthritis Emerging Drugs Profile

* Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. Currently, the drug is in Phase III stage of its development for the treatment of Knee Osteoarthritis.

* EP-104IAR: Eupraxia Pharmaceuticals Inc

EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. With EP-104IAR, Eupraxia hopes to change the way knee OA pain is treated. Currently approved corticosteroids are very effective at reducing pain for a short duration late in the disease but can expose the body to unwanted local and systemic side effects. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia's patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. A robust safety and tolerability profile would also benefit the estimated 70% of knee OA patients that experience pain in both knees by allowing simultaneous treatment of both affected joints. Currently, the drug is in Phase II stage of its development for the treatment of Knee Osteoarthritis.

* LG00034053: LG Chem

LG34053 is an injectable new drug with a new mechanism of blocking the inflammatory pathway and inhibiting chondrocyte apoptosis. LG Chem expects that the new drug will be different from existing symptomatic pain relief drugs. LG00034053 is the world's first injection-type new drug that blocks inflammatory pathways and inhibits cartilage cell death. Preclinical results showed that the pain relief effect lasted for several months with just one administration, and it also improved effects on cartilage damage, the root cause of arthritis. It has showed the possibility of developing a new drug that is different from existing pain relief symptomatic drugs. Currently, the drug is in Phase I/II stage of its development for the treatment of Knee Osteoarthritis.

If you're tracking ongoing Knee Osteoarthritis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Knee Osteoarthritis Treatment Drugs [https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Knee Osteoarthritis Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
* Knee Osteoarthritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.

Knee Osteoarthritis Companies

Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia and others.

Knee Osteoarthritis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Knee Osteoarthritis Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Knee Osteoarthritis Pipeline Report covers it all - check it out now @ Knee Osteoarthritis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Knee Osteoarthritis Pipeline Report

* Coverage- Global
* Knee Osteoarthritis Companies- Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia and others.
* Knee Osteoarthritis Therapies- Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599 and others.
* Knee Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Knee Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Knee Osteoarthritis Treatment landscape in this detailed analysis @ Knee Osteoarthritis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Knee Osteoarthritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Knee Osteoarthritis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lorecivivint: Biosplice Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EP-104IAR: Eupraxia Pharmaceuticals Inc
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* LG00034053: LG Chem
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Knee Osteoarthritis Key Companies
* Knee Osteoarthritis Key Products
* Knee Osteoarthritis Unmet Needs
* Knee Osteoarthritis Market Drivers and Barriers
* Knee Osteoarthritis Future Perspectives and Conclusion
* Knee Osteoarthritis Analyst Views
* Knee Osteoarthritis Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=knee-osteoarthritis-pipeline-drugs-insights-report-2025-emerging-therapeutics-and-market-opportunities-revealed-delveinsight]
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.